CN1589904A - Use of hemopoietic stem cell mobilizer in preparation of medicine for treating diabetes - Google Patents
Use of hemopoietic stem cell mobilizer in preparation of medicine for treating diabetes Download PDFInfo
- Publication number
- CN1589904A CN1589904A CN 03156145 CN03156145A CN1589904A CN 1589904 A CN1589904 A CN 1589904A CN 03156145 CN03156145 CN 03156145 CN 03156145 A CN03156145 A CN 03156145A CN 1589904 A CN1589904 A CN 1589904A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- hematopoietic stem
- mobilization agent
- cell mobilization
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
An application of hemopoietic stem cells mobilizing agents including cell factor, especially the granulocyte colony simulating factor, in preparing the medicine for treating diabetes is disclosed.
Description
Technical field:
The present invention relates to the purposes of hematopoietic stem cell mobilization agent, relate in particular to the purposes of preparation treatment diabetes medicament.
Background technology:
(Diabetes Mellitus, treatment DM) is one of important content of present medical research to diabetes.For accomplishing treating both the principal and secondary aspects of a disease, develop the pancreas transplantation therapy rapidly in three more than ten years in the past.But this therapy also exists many problems.On the one hand, the source of donor pancreas is very nervous, can't satisfy the demand at all; On the other hand, the immunologic rejection problem is very outstanding, and it is also big the diabetes patient to be carried out the danger that the risk of extensive abdominal operation brings than diabetes itself.
Compare with pancreas transplantation, then much safe with transplanting again after the islets of langerhans separation and purification in the donor pancreas, but, owing to from two donor pancreas, just can isolate and enough carry out islet cells and islet one time, so what this therapy made donor pancreas comes source problem more outstanding, and the patient who accepts islet transplantation still needs to take for a long time immunosuppressant.
Studies show that in recent years, hematopoietic stem cell has very strong plasticity, it can change and is divided into nerve (Proc.Natl.Acad.Sci. (1997) v94 p4080-4085), muscle (science (1998) v279 p1528-1530), liver tissues such as (Nature (2000) v406 p257).Recent research shows that also under the normal physiological state, the new life of islet cells needs the participation of hematopoietic stem cell; And by bone marrow transplantation, the diabetes that can reverse mice are (referring to Nat Biotech (2003) v21 p763-770; J Clin Invest (2003) v111 p843-850).
But still have certain distance between these results of study and the clinical practice, the receptor of bone marrow transplantation need stand heavy dose of chemicotherapy, and this is extremely dangerous to the type i diabetes people.And enough medullary cells that will find tissue matching to match are still very difficult.
The mobilization technology of hematopoietic stem cell reaches its maturity in recent years, to the understanding of its mechanism also thorough (Exp Hematol (2002) v30 p973-981) more.Existing report confirms by hematopoietic stem cell mobilization (Nature (2001) the v410 p701-705 of the cardiac muscular tissue of repairing damage effectively; Proc.Natl.Acad.Sci. (2001) v98p10344-10349).
Summary of the invention:
The objective of the invention is to set up the method for safe, reliable, efficient treatment diabetes.
Particular content of the present invention is to use the hematopoietic stem cell mobilization technology, make the hematopoietic stem cell in diabetes patient self bone marrow mobilize in the peripheral blood in a large number, make these hematopoietic stem cell participate in the reparation of diabetes patient's pancreatic endocrine cell, thereby reach the effect of reverting diabetes.
Therapeutic scheme provided by the invention is with the hematopoietic stem cell mobilization agent diabetics to be carried out hematopoietic stem cell mobilization.
Described hematopoietic stem cell mobilization agent comprises cytokine, chemotherapeutics, or the other medicines that can be used for hematopoietic stem cell mobilization known to the others skilled in the art:
Described cytokine comprises following one or more:
Granulocyte colony-stimulating factor (G-CSF); Granulocyte-huge is had a liking for colony-stimulating factor (GM-CSF); Stem cell factor (SCF); Interleukin 1 (IL-1); Interleukin (IL-3); Interleukin 8 (IL-8); Interleukin-11 (IL-11); The Fit3-aglucon; Warm albumen PIXY312; Giant cell inflammatory protein (MIP-1); SDF-1; Vascular endothelial cell growth factor (VEGF); Angiopoietin-1 etc.
Described chemotherapeutics comprises following one or more:
Cyclophosphamide (CY), cytosine arabinoside (AraC), 5-FU, etoposide (VP16); L-Sarcolysinum; Daunorubicin (DNR); Amycin; Vincristine; The methylamine pterin; Thioguanine (6TG); Prednisone; Cisplatin etc.;
Described other medicines comprise dextran sulfate etc.
Above-mentioned three class hematopoietic stem cell mobilization agent can be used a class separately, also can use wherein two classes or three classes; Every class mobilization agent all can use wherein one or more medicines.
In the above-mentioned hematopoietic stem cell mobilization agent, preferably use granulocyte colony-stimulating factor.
Advantage of the present invention is:
1. there is not immunological rejection: owing to be to mobilize autologous stem cell repairing pancreas tissue, so the risk of immunologic rejection does not take place;
2. because the multiplication capacity of hematopoietic stem cell is very strong, both can provide enough cell sources, and can not influence the normal function of hematopoietic stem cell again.
3. this therapy need not operation, and is safe, can repeatedly carry out as required.
The specific embodiment:
Embodiment
1. the preparation of diabetes model:
The C57 mice, body weight 18-22 gram, 35mg/kg dosage STZ (streptozotocin) lumbar injection, continuous five days.
2. hemopoietic is mobilized:
Matched group: injecting normal saline.
Test group: from the tenth day of start injection STZ, subcutaneous injection recombinant human granulocyte colony stimulating factor (G-CSF), using dosage were 200vg/kg/day.Logotype five days.
3. conclusion:
By utilization hematopoietic stem cell mobilization technology, make a large amount of being discharged in the peripheral blood of hematopoietic stem cell in diabetes animal model self bone marrow, make these hematopoietic stem cell participate in the reparation of pancreatic endocrine cell, thereby reach the effect of reverting diabetes.
Claims (4)
1. the hematopoietic stem cell mobilization agent is preparing the purposes for the treatment of in the diabetes medicament, and described hematopoietic stem cell mobilization agent comprises cytokine, chemotherapeutics and other medicine.
2. the purposes of diabetes medicament is treated in the described hematopoietic stem cell mobilization agent preparation of claim 1,
Described cytokine comprises following one or more: granulocyte colony-stimulating factor (G-CSF), granulocyte-huge is had a liking for colony-stimulating factor (GM-CSF), stem cell factor (SCF), interleukin 1 (IL-1), interleukin (IL-3), interleukin 8 (IL-8), interleukin-11 (IL-11), the Fit3-aglucon, warm albumen PIXY312, giant cell inflammatory protein (MIP-1), SDF-1, vascular endothelial cell growth factor (VEGF), angiopoietin-1;
Described chemotherapeutics comprises following one or more: cyclophosphamide (CY), cytosine arabinoside (AraC), 5-FU, etoposide (VP16), L-Sarcolysinum, daunorubicin (DNR), amycin, vincristine, methylamine pterin, thioguanine (6TG), prednisone, cisplatin;
Described other medicines comprise dextran sulfate.
3. the purposes of diabetes medicament is treated in the described hematopoietic stem cell mobilization agent preparation of claim 1, and wherein said hematopoietic stem cell mobilization agent is granulocyte colony-stimulating factor (G-CSF).
4. the purposes of diabetes medicament is treated in the described hematopoietic stem cell mobilization agent preparation of claim 1, and wherein said three class hematopoietic stem cell mobilization agent can be used a class separately, also can use wherein two classes or three classes; Every class mobilization agent all can use wherein one or more medicines.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03156145 CN1589904A (en) | 2003-09-01 | 2003-09-01 | Use of hemopoietic stem cell mobilizer in preparation of medicine for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03156145 CN1589904A (en) | 2003-09-01 | 2003-09-01 | Use of hemopoietic stem cell mobilizer in preparation of medicine for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1589904A true CN1589904A (en) | 2005-03-09 |
Family
ID=34598322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03156145 Pending CN1589904A (en) | 2003-09-01 | 2003-09-01 | Use of hemopoietic stem cell mobilizer in preparation of medicine for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1589904A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100353998C (en) * | 2005-07-11 | 2007-12-12 | 张利宁 | Application of combination of cytokine and hypoglycemic in treatment of diabetes |
| US20120082642A1 (en) * | 2005-08-04 | 2012-04-05 | Carlos Lopez | Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors |
| WO2014185851A1 (en) * | 2013-05-13 | 2014-11-20 | Tx Medic Ab | Dextran sulfate for use in mobilization of cells |
| CN107108719A (en) * | 2014-10-24 | 2017-08-29 | 法玛科技顾问股份有限公司 | The β of GenBank L02914-derived protein GI 193643 1（MIP‑1β）Inhibitor is used to promote angiogenesis to improve the purposes of tissue ischemia and diabetic angiopathy |
| CN107530379A (en) * | 2015-03-11 | 2018-01-02 | 佩特尼资源有限公司 | For treating the pancreatic endocrine progenitor cell therapy of obesity and diabetes B (T2D) |
-
2003
- 2003-09-01 CN CN 03156145 patent/CN1589904A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100353998C (en) * | 2005-07-11 | 2007-12-12 | 张利宁 | Application of combination of cytokine and hypoglycemic in treatment of diabetes |
| US20120082642A1 (en) * | 2005-08-04 | 2012-04-05 | Carlos Lopez | Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors |
| WO2014185851A1 (en) * | 2013-05-13 | 2014-11-20 | Tx Medic Ab | Dextran sulfate for use in mobilization of cells |
| US10258642B2 (en) | 2013-05-13 | 2019-04-16 | Tx Medic Ab | Dextran sulfate for use in mobilization of cells |
| CN107108719A (en) * | 2014-10-24 | 2017-08-29 | 法玛科技顾问股份有限公司 | The β of GenBank L02914-derived protein GI 193643 1（MIP‑1β）Inhibitor is used to promote angiogenesis to improve the purposes of tissue ischemia and diabetic angiopathy |
| CN107530379A (en) * | 2015-03-11 | 2018-01-02 | 佩特尼资源有限公司 | For treating the pancreatic endocrine progenitor cell therapy of obesity and diabetes B (T2D) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Simon et al. | Cambium cell stimulation from surgical release of the periosteum | |
| Moore et al. | Substance P increases lymphocyte traffic and lymph flow through peripheral lymph nodes of sheep. | |
| EP2347763A1 (en) | An implantable neuroendoprosthesis system, a method for preparing same and a procedure for performing of a reconstructive neurosurgical operation | |
| Chen et al. | Ginsenoside Rb1 enhances peripheral nerve regeneration across wide gaps in silicone rubber chambers | |
| CN1589904A (en) | Use of hemopoietic stem cell mobilizer in preparation of medicine for treating diabetes | |
| CN101528251B (en) | Agent comprising G-CSF for prevention and treatment of diabetic peripheral neuropathy | |
| CN101204578A (en) | Extrasin combinationpreparation for immunomodulation, preventing tissue damage and reparative regeneration | |
| US20130251669A1 (en) | Treatment of diabetes using g-csf and hyperbaric oxygen | |
| CN108938622B (en) | Composition and application thereof in preparing anti-inflammatory drugs | |
| Korompilias et al. | Interleukin‐1 beta promotes functional recovery of crushed peripheral nerve | |
| CN1772020A (en) | Freeze dried pubescent holly powder for injection and its prepn | |
| WO2006031375A2 (en) | Use of intradiscally administered autologous cells producing type i interferon for the treatment of degenerative disc disease | |
| CN100518817C (en) | Therapeutic agent to recover hematopoiesis function and its compositions and usage | |
| CN107412264A (en) | For treating the medicine and its preparation and application of male erectile disorder | |
| CN1258371C (en) | Compositions comprising organic extracts of Geum Japonicum thunb var. and the use thereof | |
| CN111214647A (en) | Medicine for treating ankylosing spondylitis | |
| RU2245162C2 (en) | Method for treating myocardial infarction | |
| Miller et al. | Tissue engineering, bioartificial organs, and cell therapies: I | |
| Orlic | Adult BM stem cells regenerate mouse myocardium | |
| US6476001B1 (en) | Facilitation of repair of neural injury with CM101/GBS toxin | |
| CN108126187A (en) | A kind of composition and preparation method | |
| Okpala et al. | Mesenchymal Stromal Cells Used for Cellular Cardiomyoplasty As a Way To Treat Myocardial Infarction and Heart Failure | |
| RU2243784C2 (en) | Method for treatment of patients with chronic hepatitis | |
| CN111035656A (en) | Method for improving life quality of diabetic by using stem cell therapy | |
| Jones et al. | The Applications of Human Umbilical Cord Mesenchymal Stem Cells to Treat Spinal Cord Injuries |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |